Abstract: Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.

Abstract: A micro-power wind-solar hybrid energy harvesting and power generating device including a solar power generation module, a wind power generation module, a control module, an energy storage module, and an accessory structure are provided. The solar power generation module is mainly composed of a solar thin film cell and a corresponding interface control circuit, and the wind power generation module includes a wind-induced vibration structure, a cantilever beam structure, a piezoelectric element, and a corresponding interface control circuit. The solar thin film cell is mounted at a top of the wind-induced vibration structure, and interface control circuits, the energy storage module, etc. are all arranged inside the wind-induced vibration structure. The control module is configured to handle an energy harvesting and power generating algorithm of the wind-solar hybrid power generating device to maximize the power generation quality and the power generation efficiency of the device.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.

Abstract: A micro-power wind-solar hybrid energy harvesting and power generating device including a solar power generation module, a wind power generation module, a control module, an energy storage module, and an accessory structure are provided. The solar power generation module is mainly composed of a solar thin film cell and a corresponding interface control circuit, and the wind power generation module includes a wind-induced vibration structure, a cantilever beam structure, a piezoelectric element, and a corresponding interface control circuit. The solar thin film cell is mounted at a top of the wind-induced vibration structure, and interface control circuits, the energy storage module, etc. are all arranged inside the wind-induced vibration structure. The control module is configured to handle an energy harvesting and power generating algorithm of the wind-solar hybrid power generating device to maximize the power generation quality and the power generation efficiency of the device.

Abstract: The present invention relates to a solid form, particularly a crystalline forms of Bcl-2 inhibitor 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide, pharmaceutical compositions comprising the solid form, processes for preparing the solid form, and methods of use therefore.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Abstract: Provided are methods and apparatuses for packet scheduling for software-defined networking in an edge computing environment. A packet scheduling method according to an exemplary embodiment of the present disclosure comprises: receiving packets arriving at a queue connected to a switch in a software-defined network in an edge computing environment; moving the packets in the queue forward one position based on the order of arrival each time a packet is served by the switch; and if a new packet enters the switch while the buffer in the queue is full, pushing out the packet at the front and putting the new packet at the end of the queue.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Abstract: Provided are methods and apparatuses for packet scheduling for software-defined networking in an edge computing environment. A packet scheduling method according to an exemplary embodiment of the present disclosure comprises: receiving packets arriving at a queue connected to a switch in a software-defined network in an edge computing environment; moving the packets in the queue forward one position based on the order of arrival each time a packet is served by the switch; and if a new packet enters the switch while the buffer in the queue is full, pushing out the packet at the front and putting the new packet at the end of the queue.

Abstract: Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR? mediated disease. The compound has the structural formula (I).

Abstract: Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR? mediated disease. The compound has the structural formula (I).

Abstract: A test system for overclocking capability of a central processing unit (CPU) includes a basic input and output system (BIOS), a frequency generator, and a watchdog timer. The BIOS includes an input module, a watchdog control module, and a frequency increasing module. The input module inputs an initial frequency of a CPU to the frequency generator to adjust a real-time frequency of the CPU. The watchdog control module sends a counter signal to the watchdog timer in a preset time interval. The watchdog timer receives the counter signal. If the watchdog timer does not receive the counter signal within the preset time, the watchdog timer outputs a reset signal to restart the computer. The frequency increasing module adds a preset increment to the real-time frequency to obtain a newly adjusted frequency, and provides the newly adjusted frequency to the frequency generator to adjust the real-time frequency.

Abstract: A method for integrating an operating system (OS) into a basic input output system (BIOS) chip and to boot a computer using programs stored in the BIOS. A bootable image file of the OS is integrated with a virtual disk program and other BIOS instructions and stored into the BIOS chip. When the computer is powered up and upon the condition that an OS in a hard disk of a computer system is damaged, the OS in the BIOS chip is executed.

Abstract: A method for integrating an operating system (OS) into a basic input output system (BIOS) chip and to boot a computer system using an image file stored in a server. A bootable image file of the OS is integrated with a virtual disk program and other BIOS instructions and stored into the BIOS chip. When the computer system is powered up, the OS stored in the BIOS can be booted to allow the another OS stored in the server to be downloaded into the harddisk and executed. The BIOS OS can also allow an OS stored on the local drive to be executed.

Abstract: The present invention relates to tetracyclodipyrano-coumarin compounds of general formula (I), wherein the substituents are defined herein. These compounds exihibit dual biological activities of anti human immunodeficiency virus type 1 (HIV-1) infection and anti-Mycobacterium Tuberculosis (TB) infection.